TW202404585A - 含有匹密特匹（Pimitespib）之醫藥組合物 - Google Patents

含有匹密特匹（Pimitespib）之醫藥組合物 Download PDF

Info

Publication number
TW202404585A
TW202404585A TW112121639A TW112121639A TW202404585A TW 202404585 A TW202404585 A TW 202404585A TW 112121639 A TW112121639 A TW 112121639A TW 112121639 A TW112121639 A TW 112121639A TW 202404585 A TW202404585 A TW 202404585A
Authority
TW
Taiwan
Prior art keywords
pharmaceutical composition
crystalline cellulose
tablet
manufactured
mass
Prior art date
Application number
TW112121639A
Other languages
English (en)
Chinese (zh)
Inventor
西山哲矢
仁木悠一郎
Original Assignee
日商大鵬藥品工業股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商大鵬藥品工業股份有限公司 filed Critical 日商大鵬藥品工業股份有限公司
Publication of TW202404585A publication Critical patent/TW202404585A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW112121639A 2022-06-10 2023-06-09 含有匹密特匹（Pimitespib）之醫藥組合物 TW202404585A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2022094420 2022-06-10
JP2022-094420 2022-06-10

Publications (1)

Publication Number Publication Date
TW202404585A true TW202404585A (zh) 2024-02-01

Family

ID=89118411

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112121639A TW202404585A (zh) 2022-06-10 2023-06-09 含有匹密特匹（Pimitespib）之醫藥組合物

Country Status (10)

Country Link
US (1) US20250312280A1 (https=)
EP (1) EP4537824A1 (https=)
JP (1) JPWO2023238929A1 (https=)
KR (1) KR20250022143A (https=)
CN (1) CN119365195A (https=)
AU (1) AU2023282693A1 (https=)
CA (1) CA3258968A1 (https=)
MX (1) MX2024015327A (https=)
TW (1) TW202404585A (https=)
WO (1) WO2023238929A1 (https=)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4608087B2 (ja) * 1999-12-22 2011-01-05 富山化学工業株式会社 固形製剤の製造法
PT2452940E (pt) 2009-07-10 2015-02-27 Taiho Pharmaceutical Co Ltd Composto azabiciclo e seu sal
EP2498759B1 (en) * 2009-11-13 2018-08-01 AstraZeneca AB Immediate release tablet formulations
MX353289B (es) * 2011-05-25 2018-01-05 Taiho Pharmaceutical Co Ltd Tableta revestida en seco que contiene tegafur, gimeracil y oteracil potasico.
RU2657783C2 (ru) 2013-09-30 2018-06-15 Тайхо Фармасьютикал Ко., Лтд. Комбинированная терапия с использованием азабициклосоединения для ракового заболевания
JP6537601B2 (ja) 2015-05-12 2019-07-03 大鵬薬品工業株式会社 アザ二環式化合物の結晶
DK3646869T3 (da) 2017-06-30 2025-09-15 Taiho Pharmaceutical Co Ltd Kemoterapi mod kræft under anvendelse af azabicycloforbindelse
BR112020005100A2 (pt) 2017-09-15 2020-09-15 Taiho Pharmaceutical Co., Ltd. usos de um composto inibidor de hsp90 para produzir um agente profilático e/ou terapêutico para doenças que envolvem expressão de ido e para produzir uma composição farmacêutica para tratar tumores ido-positivos
JP6918204B2 (ja) * 2018-03-19 2021-08-11 大鵬薬品工業株式会社 アルキル硫酸ナトリウムを含む医薬組成物
AU2018423606B2 (en) 2018-05-14 2024-10-10 Taiho Pharmaceutical Co., Ltd. Method of treating malignant tumor by azabicyclic compound

Also Published As

Publication number Publication date
CA3258968A1 (en) 2025-04-18
EP4537824A1 (en) 2025-04-16
CN119365195A (zh) 2025-01-24
KR20250022143A (ko) 2025-02-14
WO2023238929A1 (ja) 2023-12-14
US20250312280A1 (en) 2025-10-09
MX2024015327A (es) 2025-02-10
AU2023282693A1 (en) 2025-01-02
JPWO2023238929A1 (https=) 2023-12-14

Similar Documents

Publication Publication Date Title
KR101840182B1 (ko) 4-아미노-5-플루오로-3-[6-(4-메틸피페라진-1-일)-1ｈ-벤즈이미다졸-2-일]-1ｈ-퀴놀린-2-온 락테이트 일수화물을 포함한 제약 조성물
JP7096164B2 (ja) ジアミン誘導体を含む口腔内崩壊錠
TWI790364B (zh) 包含烷基硫酸鈉之醫藥組合物
JP2010530355A (ja) 医薬固形製剤及びその製造方法
CN111565720A (zh) 控释制剂
CN116133646A (zh) 普拉替尼药物组合物
JP2025108517A (ja) ピロールカルボキサミドを含む口腔内崩壊錠
TW200808358A (en) Galenical formulations of organic compounds
CN113491695A (zh) 一种仑伐替尼药物组合物、其制备方法及应用
TW202404585A (zh) 含有匹密特匹（Pimitespib）之醫藥組合物
RU2857663C2 (ru) Фармацевтическая композиция, содержащая пимитеспиб
JP6116847B2 (ja) シクロデキストリンとの混合体を含有する錠剤
WO2022042646A1 (zh) 盐酸鲁拉西酮组合物及其制备方法
HK40115959A (zh) 含有匹米替比的医药组合物
TWI918738B (zh) 布瓦西坦藥物組合物、其製備方法及應用
JP7581712B2 (ja) アビラテロン酢酸エステル含有製剤
KR102511672B1 (ko) 의약 조성물, 그 제조방법 및 사용
JP2018020968A (ja) ゲフィチニブを有効成分とする医薬組成物
CN107205984B (zh) 吡咯甲酰胺的固体组合物
TW202602449A (zh) ２－［（３ｒ）－２－［４－胺基－３－（２－氟－４－苯氧基－苯基）吡唑並［３，４－ｄ］嘧啶－１－基］哌啶－１－羰基］－４－甲基－４［４－（氧雜環丁烷－３－基）哌－１－基］－戊－２－烯腈的調配物
KR20250041176A (ko) 나포라페닙을 포함하는 무정형 고체 분산물
TW202333702A (zh) 具有優異溶出性之醫藥組成物
HK40082826A (en) Orally disintegrating tablet containing mirogabalin besilate
WO2022034914A1 (ja) 易溶性固形製剤およびその製法
JP2021070658A (ja) アビラテロン酢酸エステル含有製剤